3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
20
Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, Follicular
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Neoplasms
2
Leukemia, B-Cell
2
Stomach Neoplasms
1
Hodgkin Disease
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Chlorambucil
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts
NCT01657955
2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3
Unknown
96 enrolled